Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Cephalon )
ClinicalTrials.gov Identifier:
NCT00586651
First received: December 21, 2007
Last updated: August 22, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2010
  Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 22, 2013